A breakthrough in the understanding and management of Duchenne muscular dystrophy (DMD) has been announced with the launch of a novel prognostic score. This crucial tool, developed by the Collaborative Trajectory Analysis Project (cTAP), is designed to predict when patients will lose their ability to walk, allowing clinicians to better plan care and inform research efforts.
The new score relies on two simple yet effective assessments: how long it takes a patient to get up from the floor, and their performance in a 10-meter walk/run test. According to Dr Craig McDonald, Professor at the University of California at Davis Medical Center, this easy-to-use tool will enable healthcare professionals to provide more accurate advice to patients and their families, improve trial design, and ultimately enhance the quality of care for those living with Duchenne.
Duchenne muscular dystrophy is a severe genetic disorder that affects approximately 1 in 3,500 to 1 in 6,000 live male births. It causes progressive muscle degeneration and eventual loss of motor function, leading to early death often due to heart and lung failure. The loss of mobility is one of the biggest challenges for patients and their families, making accurate prediction crucial for planning and intervention.
The study demonstrated that the prognostic score categorises patients into five distinct risk groups with well-separated prognoses. The lowest-risk group can expect to keep their independence for over four years, while those in the highest-risk group may lose mobility within a year. Crucially, the score was validated using an independent dataset, confirming its reliability and ability to be used more widely.
The implications of this score extend beyond individual patient care. In clinical practice, it will enable healthcare providers to offer more tailored guidance on mobility aids, home modifications, and psychosocial support. For clinical trials, the score holds the potential to streamline patient selection, making research more efficient by identifying groups with similar prognostic trajectories, which could accelerate the development of new treatments.
Debra Miller, founder and CEO of CureDuchenne, a founding patient advocacy partner and initial seed funder, commented that this breakthrough is 'a significant step forward' in the understanding and management of Duchenne. She added: 'This tool has the potential to improve the lives of patients with DMD and their families by providing more accurate predictions and better informing treatment decisions.'
The research was published on 26 May 2026 in Neurology, the medical journal of the American Academy of Neurology. The new score is based on data from over 600 boys with DMD, drawn from natural history databases and clinical trial placebo arms.